Birgit Kjældgaard Giwercman
Chief Executive Officer at BKG Pharma ApS
Birgit Kjældgaard Giwercman active positions
| Companies | Position | Start | End |
|---|---|---|---|
BKG Pharma ApS
 BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Founder | 15/03/2010 | - |
| Chief Executive Officer | 15/03/2010 | - | |
| Director/Board Member | 01/01/2004 | - | |
| BKG Vet Pharma ApS | Chief Executive Officer | 01/01/2011 | - |
Career history of Birgit Kjældgaard Giwercman
Former positions of Birgit Kjældgaard Giwercman
| Companies | Position | Start | End |
|---|---|---|---|
Pantheco A/S
 Pantheco A/S Pharmaceuticals: MajorHealth Technology Pantheco A/S is a Danish biotech company, whose mission it is to develop drugs based upon Peptide Nucleic Acid (PNA) for the treatment of infectious diseases caused by resistant microorganisms. Pantheco represents a spin-off of the research activities and know-how within the Peptide Nucleic Acid (PNA) antisense technology invented at University of Copenhagen in 1992 and the PNA Patent Rights licensed from Isis Pharmaceuticals, Inc. in US. By employing the PNA technology, chemistry, know-how, and the exclusive rights for human therapeutic uses within anti-infectives, Pantheco has the unique opportunity to generate novel classes of anti-infective drugs and become a world class leader within novel generations of antisense therapeutics. | Director/Board Member | - | - |
Cureon A/S
 Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Director/Board Member | - | - |
| University of Copenhagen | Corporate Officer/Principal | - | - |
Training of Birgit Kjældgaard Giwercman
| University of Copenhagen | Doctorate Degree |
Statistics
International
| Denmark | 6 |
Operational
| Director/Board Member | 3 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
BKG Pharma ApS
BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Health Technology |
Pantheco A/S
Pantheco A/S Pharmaceuticals: MajorHealth Technology Pantheco A/S is a Danish biotech company, whose mission it is to develop drugs based upon Peptide Nucleic Acid (PNA) for the treatment of infectious diseases caused by resistant microorganisms. Pantheco represents a spin-off of the research activities and know-how within the Peptide Nucleic Acid (PNA) antisense technology invented at University of Copenhagen in 1992 and the PNA Patent Rights licensed from Isis Pharmaceuticals, Inc. in US. By employing the PNA technology, chemistry, know-how, and the exclusive rights for human therapeutic uses within anti-infectives, Pantheco has the unique opportunity to generate novel classes of anti-infective drugs and become a world class leader within novel generations of antisense therapeutics. | Health Technology |
Cureon A/S
Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Health Technology |
| BKG Vet Pharma ApS |
